ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 255 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q1 2023. The put-call ratio across all filers is 0.89 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $56,032 | -47.4% | 2,206 | -16.0% | 0.00% | -40.0% |
| Q4 2022 | $106,511 | +3.4% | 2,626 | -15.5% | 0.01% | -16.7% |
| Q3 2022 | $103,000 | -29.5% | 3,108 | -25.1% | 0.01% | -14.3% |
| Q2 2022 | $146,000 | -23.6% | 4,150 | 0.0% | 0.01% | -12.5% |
| Q1 2022 | $191,000 | -33.4% | 4,150 | -4.1% | 0.01% | -20.0% |
| Q4 2021 | $287,000 | -34.2% | 4,328 | -38.1% | 0.01% | -28.6% |
| Q3 2021 | $436,000 | -48.6% | 6,991 | -31.7% | 0.01% | -30.0% |
| Q2 2021 | $848,000 | +33.3% | 10,236 | +6.7% | 0.02% | +33.3% |
| Q1 2021 | $636,000 | -14.5% | 9,592 | -1.1% | 0.02% | -6.2% |
| Q4 2020 | $744,000 | +7.7% | 9,701 | -39.6% | 0.02% | +6.7% |
| Q3 2020 | $691,000 | -29.7% | 16,050 | -29.5% | 0.02% | -31.8% |
| Q2 2020 | $983,000 | +158.7% | 22,754 | +72.1% | 0.02% | +144.4% |
| Q1 2020 | $380,000 | -72.8% | 13,221 | -40.0% | 0.01% | -71.0% |
| Q4 2019 | $1,397,000 | +125.3% | 22,019 | 0.0% | 0.03% | +121.4% |
| Q3 2019 | $620,000 | – | 22,019 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Western Financial Corp/CA | 820,320 | $33,272,179 | 21.56% |
| Aquilo Capital Management, LLC | 1,103,515 | $44,758,568 | 16.81% |
| M28 Capital Management LP | 143,900 | $5,836,584 | 5.56% |
| WEALTH EFFECTS LLC | 155,620 | $6,311,951 | 3.60% |
| Evolutionary Tree Capital Management, LLC | 92,095 | $3,735,373 | 3.59% |
| Privium Fund Management B.V. | 221,015 | $8,867,122 | 3.36% |
| JOHNSON & JOHNSON | 247,598 | $10,043 | 2.92% |
| COMMODORE CAPITAL LP | 462,111 | $18,743 | 2.82% |
| Avidity Partners Management LP | 1,375,000 | $55,770,000 | 1.21% |
| Capital Impact Advisors, LLC | 26,853 | $1,089,158 | 1.06% |